Company profile
VectivBio company profile
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
Business identity
- Website
- https://vectivbio.com
- Contact email
- [email protected]
- Operating status
- Closed
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $1M-$10M
- Founded
- 2019-01-01, Year
Headquarters
- Headquarters
- Breíl, Grisons, Switzerland
- Postal code
- 4051
- Country code
- CH
- Continent
- Europe